Last reviewed · How we verify
DA-1229_01 fed
At a glance
| Generic name | DA-1229_01 fed |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State (PHASE1)
- Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State (PHASE1)
- Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State (PHASE1)
- A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State (PHASE1)
- A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State (PHASE1)
- A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-1229_01 fed CI brief — competitive landscape report
- DA-1229_01 fed updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI